Dr. Cortes On Tyrosine Kinase Inhibitors In Cml

Dr. Cortes on Tyrosine Kinase Inhibitors in CML

Dr. Cortes Discusses TKI Cessation in CML

Tyrosine Kinase Inhibitors (TKIs) - Imatinib (Gleevec) - Pharmacology - CML and ALL

Medicosis Perfectionalis

How to Treat Chronic Myeloid Leukemia (CML) - Dr. Jorge Cortes

OncBrothers: Practice-Changing Cancer Discussions

Jorge Cortes, MD, Shares Data on Asciminib Versus TKIs in CML

Blood Cancers Today

Dr. Cortes on the 192-Week Follow-Up Results of the ENESTop Trial in CML

Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial

Updates in CML Management – Dr. Jorge Cortes (May 26-27, 2023)

SSBMT جمعية الخلايا الجذعية

Efficacy and safety of vodobatinib by lines of TKI therapy in Ph+ CML: a subgroup analysis

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Cortes on Ponatinib in Patients with CML and Ph+ALL

Targeted Oncology

Chronic Myeloid Leukemia (CML) - Treatment - Tyrosine Kinase (TK) Inhibitors

Medicosis Perfectionalis

CML Treatment: Old Drug, New Name

MDedge: news and insights for busy physicians

Dr. Jorge Cortes on the Phase II Ponatinib PACE Trial

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

Dr. Cortes Discusses Ponatinib as Initial Therapy for CML

CML as an Ideal Cancer for Targeted Therapy With TKI

Targeted Oncology

Asciminib versus other TKIs in the frontline treatment of CML: the ASC4FIRST study

VJHemOnc – Video Journal of Hematology & HemOnc

Jorge Cortes, MD, on the Evolution of CML Treatment, Remaining Challenges

Blood Cancers Today

Jorge Cortes, MD, provides thoughts on what the impact of the OPTIC study will be on CML patients

Treatment of CML with TKI’s